Analyst consensus rating
Kyverna Therapeutics Analyst Rating: Strong Buy
Direct answer
Kyverna Therapeutics's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.40.
Forecast evidence checked September 17, 2026.
Get free Kyverna Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.90
- Average price target
- $30.40
- High price target
- $33.00
- Low price target
- $25.00
- Low target gap
- +262.3%
- Target upside
- +340.6%
- High target gap
- +378.3%
- Target range width
- 115.9%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- September 17, 2026
- Valid through
- September 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kyverna Therapeutics?
Kyverna Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $30.40.
How far are Kyverna Therapeutics's low and high targets from the recorded price?
The low target implies +262.3%, while the high target implies +378.3%.
How many analysts are included in Kyverna Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Kyverna Therapeutics's target upside or downside calculated?
The average target of $30.40 is divided by the recorded price of $6.90, then one is subtracted to produce +340.6%. This does not guarantee a future return.
When was Kyverna Therapeutics's analyst forecast verified?
The data was verified on 2026-09-17. The dataset is valid through 2026-09-24.